Tenderwize
Back to tender search

Open house Arzneimittelrabattverträge Fremanezumab, ATC N02CD03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 535 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fremanezumab, ATC N02CD03

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

10 / 100

Risk factors

No indication of the expected number of patients or sales volume, making revenue estimation impossible.

Open-house agreements automatically become void if a regular rebate contract for the same substance is signed, potentia...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive pharmaceutical discount agreements for Fremanezumab (ATC N02CD03)
  • Single lot covering the active substance only
Show full summary

This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive pharmaceutical discount agreements for Fremanezumab (ATC N02CD03). Any qualified pharmaceutical company can join at any time during the contract period (01.04.2026 – 31.03.2028). There is no selection, no competition, and no estimated value disclosed. The tender is governed by German social law (§130c SGB V) and explicitly excluded from procurement law. Only one lot is defined.

Risks

No indication of the expected number of patients or sales volume, making revenue estimation impossible.

Open-house agreements automatically become void if a regular rebate contract for the same substance is signed, potentia...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Eligibility

  • Only pharmaceutical companies are eligible as contractual partners

Administrative

  • Submission of a signed and completed 'Eigenerklärung zur Zuverlässigkeit' (declaration of reliability)
  • Submission of the signed contract including the annex 'Festlegung der vertragsgegenständlichen Arzneimittel'

Requirements may be incomplete.

Buyer

Location

München, DEU

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Fremanezumab, ATC N02CD03

Non-exclusive discount agreements for the active substance Fremanezumab (ATC N02CD03). Contractual terms are identical and non-negotiable. Contracts have a fixed end date of 31.03.2028. Earliest start is 01.04.2026. Submission of signed contract and reliability declaration required. Submission via paper or electronically with qualified electronic signature.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Mar 2026 - Mar 2028

Category

Pharmaceutical products

Deadline

Deadline Feb 03, 2028

Procurement Details

Publication date
15 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
109906-2026

Documents (2)

Similar tenders